3e94d9d5-8c59-4366-babb-193bdc57d661
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.500
- MYC_TARGETS_V1+0.400
- MYC_TARGETS_V2+0.400
- ANGIOGENESIS+0.300
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.300
- G2M_CHECKPOINT+0.300
- TNFA_SIGNALING_VIA_NFKB+0.300
- UNFOLDED_PROTEIN_RESPONSE+0.300
- DNA_REPAIR+0.200
- GLYCOLYSIS+0.200
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.500
- INTERFERON_GAMMA_RESPONSE-0.400
- ALLOGRAFT_REJECTION-0.300
- BILE_ACID_METABOLISM-0.300
- COMPLEMENT-0.200
- ESTROGEN_RESPONSE_EARLY-0.200
- FATTY_ACID_METABOLISM-0.200
- HEME_METABOLISM-0.200
- KRAS_SIGNALING_DN-0.200
- PEROXISOME-0.200
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR5088878 | — | — | 0.818 |
| 2 | MNG732 | — | — | 0.795 |
| 3 | 5572a203-73b9-4a85-b47d-af228abca5b1 | — | — | 0.792 |
| 4 | SRR8613735 | — | E | 0.787 |
| 5 | TCGA-D8-A27F-01A-11R-A16F-07 | — | E | 0.773 |
| 6 | 350f38a2-e597-494a-a387-975814453726 | — | — | 0.770 |
| 7 | MNG495 | — | — | 0.770 |
| 8 | MDT-AP-0399 | Med | Medulloblastoma | 0.766 |
| 9 | SRR12202460 | — | — | 0.765 |
| 10 | TCGA-OR-A5KZ-01 | Adrenocortical Carcinoma | Adrenocortical Carcinoma, Usual Type | 0.764 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 23 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.500 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.400 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.400 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.300 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.300 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.300 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.300 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.300 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.200 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.200 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.200 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.200 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.100 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.100 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.100 | Inavolisib | — uncovered |
| HYPOXIA | 0.100 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.100 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.100 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.100 | Cobimetinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.100 | Inavolisib | — uncovered |